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Summary
Burkholderia mallei, the aetiologic agent of glanders,
causes a variety of illnesses in animals and humans
ranging from occult infections to acute fulminating
septicaemias. To better understand the role of
lipopolysaccharide (LPS) in the pathogenesis of these
diseases, studies were initiated to characterize the
structural and biological properties of lipid A moieties
expressed by this organism. Using a combination of
chemical analyses and MALDI-TOF mass spectrom-
etry, B. mallei was shown to express a heterogeneous
mixture of tetra- and penta-acylated lipid A species
that were non-stoichiometrically substituted with
4-amino-4-deoxy-arabinose residues. The major
penta-acylated species consisted of bisphosphory-
lated D-glucosamine disaccharide backbones pos-
sessing two amide linked 3-hydroxyhexadecanoic
acids, two ester linked 3-hydroxytetradecanoic acids
[C14:0(3-OH)]andanacyloxyacyllinkedtetradecanoic
acid, whereas, the major tetra-acylated species pos-
sessed all but the 3-linked C14:0(3-OH) residues. In
addition, although devoid of hexa-acylated species,
B. mallei LPS was shown to be a potent activator of
human Toll-like receptor 4 complexes and stimulated
human macrophage-like cells (THP-1 and U-937),
monocyte-derived macrophages and dendritic cells to
producehighlevelsofTNF-a,IL-6andRANTES.Based
upon these results, it appears that B. mallei LPS is
likely to play a signiﬁcant role in the pathogenesis of
human disease.
Introduction
Burkholderia mallei, the aetiologic agent of glanders,
is a non-motile, aerobic, facultative-intracellular Gram-
negative bacillus that is primarily responsible for disease
in horses, mules, donkeys and occasionally humans
(Howe and Miller, 1947; Redfearn et al., 1966; Yabuuchi
et al., 1992; Srinivasan et al., 2001). In horses, glanders
presents as chronic or acute illnesses characterized pri-
marily by lung involvement, ulcerative nasal and tracheal
lesions and visceral abscess formation. In contrast,
farcy, the cutaneous form of the disease, is character-
ized by the presence of nodules and ulcerative skin
lesions on the extremities of the animals (Redfearn
et al., 1966; Howe et al., 1971; Bartlett, 2005). The clini-
cal progression of human glanders is similar to that
observed in solipeds and may manifest as chronic or
acute localized infections, acute pulmonary infections or
fulminating septicaemias. Although rare, human infec-
tions are thought to be acquired via the inoculation of
mucosal or cutaneous tissues with aerosols or secre-
tions from diseased animals. In the absence of chemo-
therapeutic intervention human glanders is invariably
fatal (Dance, 1996; Bartlett, 2005). Due to this, the
Centers for Disease Control and Prevention have listed
B. mallei as a category B biological threat agent (Rotz
et al., 2002). Currently, there are no human or veterinary
vaccines commercially available for immunization
against these diseases.
Although glanders is one of the oldest of known infec-
tious diseases, the molecular mechanisms by which
B. mallei causes disease remain poorly deﬁned (Wilkin-
son, 1981). Recently, however, a number of groups have
demonstrated that quorum sensing, type three secretion
system and capsular polysaccharide (CPS) mutants are
attenuated in their ability to cause disease in mice, golden
hamsters and/or miniature horses (DeShazer et al., 2001;
Lopez et al., 2003; Ulrich and DeShazer, 2004; Ulrich
et al., 2004). In addition, we have previously shown that
B. mallei strains expressing rough lipopolysaccharide
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cidal effects of normal human serum than are those
expressing a smooth phenotype also implicating LPS as
potential virulence determinant (Burtnick et al., 2002).
Lipopolysaccharides, commonly referred to as endotox-
ins, are a major component of Gram-negative cell enve-
lopes (Burns et al., 2006). The ‘barrier function’ provided
by bacterial outer membranes is largely due to the pres-
ence of these molecules (Nikaido, 2003). Bacterial strains
expressing a ‘smooth’ phenotype synthesize LPS anti-
gens that are composed of three covalently linked
domains: an O-antigen, a core region and a lipid A moiety
(Raetz and Whitﬁeld, 2002). Lipid A, which normally func-
tions as the hydrophobic membrane-anchor component of
LPS, is also the domain responsible for stimulating a
variety of pathophysiological responses in mammals
(Alexander and Rietschel, 2001; Trent, 2004). In general,
bisphosphorylated hexa-acylated lipidAspecies possess-
ing C12 and C14 fatty acids represent the most biologi-
cally active forms of the molecule (Erridge et al., 2002;
Raetz and Whitﬁeld, 2002; Caroff and Karibian, 2003).
Lipid A moieties that deviate from this pattern often dem-
onstrate a signiﬁcant decrease in endotoxic activity (Alex-
ander and Rietschel, 2001; Backhed et al., 2001; 2003).
Host recognition of LPS antigens by mammalian cells is
mediated through interactions with Toll-like receptor 4
(TLR4) complexes. These complexes, consisting of TLR4
receptors and the MD2 and CD14 coreceptors enable a
variety of cell types to rapidly detect the presence of
Gram-negative bacteria in host tissues (Poltorak et al.,
1998; da Silva Correia et al., 2001; Miller et al., 2005).
Monocytes and macrophages, for instance, when acti-
vated by LPS through TLR4 complexes secrete pro-
inﬂammatory cytokines such as TNF-a, IL-1b and IL-6
which augment innate immune responses against invad-
ing microbes. In excess, however, these cytokines can
cause multiple organ failure, shock and death (Zanotti
et al., 2002). Although studies have examined some
structural aspects of B. mallei LPS, none have actually
reported on a potential immunopathological role for this
molecule (Pitt et al., 1992; Anuntagool and Sirisinha,
2002; Woods et al., 2002). In order to address this issue,
we have utilized a combination of genetic, chemical,
physical and immunological approaches to further char-
acterize the LPS expressed by this bacterial pathogen.
The main objective of this study was to develop a better
understanding of the potential role of endotoxin in the
pathogenesis of disease caused by this organism.
Results
Characterization of puriﬁed LPS antigens
In order to obtain highly puriﬁed LPS for use in this study,
endotoxin was isolated from B. mallei GM3773 (CPS
mutant) as well as ATCC 23344 (wild-type strain) using a
modiﬁed enzyme hot aqueous-phenol procedure. SDS-
PAGEandsilverstainanalysisoftheLPSisolatedfromthe
CPS mutant demonstrated that the preparation consisted
of a mixture of both rough and smooth species. Further
examination of the gel revealed no apparent structural
differences between the LPS species isolated from the
CPS mutant and wild-type strain (Fig. 1A). Similar results
were also observed by immunoblot analysis (data not
shown). Additional analysis of the samples by enzyme-
linked immunosorbent assays (ELISA), however, demon-
strated that while the GM3773 preparation contained no
detectable levels of the CPS, the LPS isolated fromATCC
23344wascontaminatedwiththisantigen(Fig. 1B).Based
upon these ﬁndings, as well as those from the chemical
and MALDI-TOF-MS analyses (see below), we opted to
utilize the LPS isolated from GM3773 to determine the
biological activities associated with B. mallei endotoxin.
Composition and chemical analyses of lipid A
Lipid A samples were isolated from the puriﬁed LPS
preparations via mild acid hydrolysis. Glycosyl composi-
tion analysis of lipid A obtained from B. mallei GM3773
LPS conﬁrmed the presence of D-glucosamine (GlcN) in
the sample. Fatty acid composition analysis of the lipid A
sample also revealed the presence of tetradecanoic
(C14:0), 3-hydroxytetradecanoic [C14:0(3-OH)], hexade-
canoic (C16:0) and 3-hydroxyhexadecanoic acids
[C16:0(3-OH)] in the molar ratios of ~1.0:1.6:0.2:1.9
Fig. 1. Analysis of puriﬁed LPS preparations.
A. SDS-PAGE. The B. mallei ATCC 23344 and GM3773 LPS
preparations (1 mg lane
-1) were electrophoresed on 12% Express
Gels and visualized by silver staining.
B. CPS-speciﬁc ELISA. Microtiter plate wells were coated with the
ATCC 23344 or GM3773 LPS preparations (500 ng well
-1) and then
incubated with the MCA147 mAb to assay for the presence of CPS.
Error bars represent the standard deviation of samples assayed in
quadruplicate. The ﬁgure is representative of two independent
experiments.
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onstrated that the C14:0, C14:0(3-OH) and C16:0 resi-
dues were ester linked indicating that the C16:0(3-OH)
residues were amide linked. Similar results were also
obtained for the lipidAantigens isolated from the B. mallei
ATCC 23344 LPS.
MALDI-TOF-MS analyses of lipid A
The negative-ion MALDI-TOF mass spectrum of the puri-
ﬁed B. mallei GM3773 lipid A preparation revealed a
complex pattern of molecular ion peaks indicative of a
heterogeneous mixture of species (Fig. 2A). Utilizing the
information obtained from chemical and composition
analyses in combination with the MS data, the molecular
ionpeakswereassignedasfollows.Thefourmainseriesof
ion peaks identiﬁed were representative of a combination
of tetra-acylated (m/z 1448 and 1579) and penta-acylated
(m/z 1675 and 1806) species (Table 1). These species
were also present in signiﬁcant quantities as sodium
adducts (Dm/z + 22). The ion at m/z 1448 (species 1) was
consistent with a tetra-acylated bisphosphorylated GlcN
disaccharide backbone possessing C14:0 and C14:0(3-
OH) residues in ester linkage and two C16:0(3-OH) resi-
duesinamidelinkage.Theionatm/z1579(species2)was
representative of species 1 modiﬁed with a 4-amino-4-
deoxy-arabinose (Ara4N) residue (Dm/z + 131). The ion at
m/z 1675 (species 3) was consistent with a penta-acylated
bisphosphorylated GlcN disaccharide backbone possess-
ing one C14:0 residue and two C14:0(3-OH) residues in
ester linkage and two C16:0(3-OH) residues in amide
linkage. The ion at m/z 1806 (species 4) was representa-
tiveofspecies3modiﬁedwithanAra4Nresidue.Theminor
ion peak at m/z 1959 (species 5) was representative of a
species 3 sodium adduct modiﬁed with two Ara4N resi-
dues. Taking into account the results of the fatty acid
Fig. 2. Negative-ion MALDI-TOF mass
spectra of lipid A species isolated from
puriﬁed LPS antigens. (A) B. mallei GM3773
and (B) ATCC 23344 mass spectra. The
molecular ion peaks (1–5) are described in
Table 1 or in the text. Sodium adducts
(Dm/z + 22) are not labelled.
Table 1. Main MALDI-TOF-MS negative-ion peaks and the proposed interpretation of the fatty acid, phosphate and carbohydrate substituents on
the B. mallei GM3773 lipid A backbone.
Lipid A
species
a
Observed
ion (m/z)
Calculated
ion (Da)
Acyl
substitution Predicted fatty acid, phosphate and Ara4N composition
1 1448 1445.4 Tetra C14:0(3-OH), 2 ¥ C16:0(3-OH), C14:0, 2 ¥ P
2 1579 1576.5 Tetra C14:0(3-OH), 2 ¥ C16:0(3-OH), C14:0, 2 ¥ P, Ara4N
3 1675 1671.3 Penta 2 ¥ C14:0(3-OH), 2 ¥ C16:0(3-OH), C14:0, 2 ¥ P
4 1806 1802.3 Penta 2 ¥ C14:0(3-OH), 2 ¥ C16:0(3-OH), C14:0, 2 ¥ P, Ara4N
a. Sodium adducts (Dm/z + 22) are not listed.
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to contain similar ratios of the tetra- and penta-acylated
species. Similar results were obtained for LPS isolated
from B. mallei ATCC 23344 conﬁrming that lipid A species
expressed by the wild type and CPS mutant strains were
identical to one another (Fig. 2B).
The positive-ion MALDI-TOF mass spectrum of the
puriﬁed B. mallei GM3773 lipid A preparation demon-
strated the presence of a number of diagnostic oxonium
ions (m/z 984, 956, 736 and 730) arising from the cleav-
age of the glycosidic linkage between the reducing and
non-reducing GlcN residues of the lipid A backbone. The
major oxonium ion observed at m/z 956 was consistent
with the sodium adduct of a non-reducing GlcN possess-
ing one ester linked C14:0 residue, one ester linked
C14:0(3-OH) residue and one amide linked C16:0(3-OH)
residue. In contrast, the minor ion observed at m/z 984
was consistent with a non-reducing GlcN possessing one
ester linked C16:0 residue, one ester linked C14:0(3-OH)
residue and one amide linked C16:0(3-OH) residue
(Fig. 3). In addition, the major oxonium ion observed at
m/z 730 was consistent with the sodium adduct of a
non-reducing GlcN possessing an amide linked C16:0(3-
OH) residue esteriﬁed by a C14:0 residue while the minor
ion observed at m/z 736 was consistent with a non-
reducing GlcN possessing an amide linked C16:0(3-OH)
residue esteriﬁed by a C16:0 residue (data not shown).
Based upon the results of these analyses the proposed
structures of the major lipid A species identiﬁed in this
study are depicted in Fig. 4.
Burkholderia mallei LPS is a potent activator of hTLR4
complexes
Lipopolysaccharide can activate a variety of cell types
through interactions with TLR4 complexes (Fujihara
et al., 2003). The magnitude of cell activation, however,
is greatly inﬂuenced by endotoxin structure (Backhed
et al., 2003). In order to characterize the ability of
B. mallei LPS to function as a hTLR4 agonist, HEK 293
cells expressing hMD2-CD14, hTLR2-CD14 or hTLR4-
MD2-CD14 were stimulated with varying concentrations
of endotoxin and the culture supernatants were assayed
for IL-8. The results of these studies demonstrated that
when stimulated with the B. mallei LPS, the HEK 293-
hTLR4/MD2-CD14 cells produced dose-dependent IL-8
responses that were similar to those observed when
stimulated with the Escherichia coli O55:B5 LPS control.
In contrast, the HEK 293-hTLR2/CD14 cells secreted
signiﬁcantly lower levels of IL-8 when stimulated with
identical concentrations of the LPS samples (Fig. 5). In
addition, neither of the E. coli or B. mallei LPS prepara-
tions stimulated responses from the HEK 293-hMD2-
CD14 cells at any of the concentrations tested (0.1–
100 ng ml-1; data not shown). Based upon the results of
these assays, B. mallei LPS was shown to be a potent
activator of hTLR4-complexes.
Burkholderia mallei endotoxin activates human
macrophages and dendritic cells
Antigen presenting cells (APCs) such as macrophages
and dendritic cells recognize bacteria through TLRs and
other pattern recognition receptors. Stimulation of APCs
through these receptors activates signal transduction cas-
cades that culminate in the production of cytokines,
chemokines and other costimulatory molecules. To test
the ability of B. mallei LPS to activate human APCs,
Fig. 3. Positive-ion MALDI-TOF mass spectra of lipid A isolated
from B. mallei GM3773. The signiﬁcance of the major (m/z 956)
and minor (m/z 984) oxonium ion peaks are described in the text.
Fig. 4. Predicted structures of the major lipid A species identiﬁed in
this study. Non-stoichiometric substitutions are depicted in blue
(Ara4N) and red [C14:0(3-OH)].
382 P. J. Brett et al.
Journal compilation © 2006 Blackwell Publishing Ltd, Molecular Microbiology, 63, 379–390
No claim to original US government worksmacrophage-like THP-1 cells were stimulated with
10 ng ml-1 of LPS isolated from GM3773 and the culture
supernatants were assayed for the production of speciﬁc
cytokines and chemokines. When stimulated with
GM3773 LPS, THP-1 cells produced TNF-a, IL-6 and
RANTES responses that were similar to those detected
using E. coli O55:B5 LPS as a control (Fig. 6). Similar
trends were also observed when the macrophage-like
U-937 cells were stimulated with B. mallei LPS (data not
shown). In addition, studies demonstrated that when
MDM were stimulated with B. mallei LPS, they produced
high levels of TNF-a, IL-6 and RANTES (Fig. 7). Further-
more, when stimulated with B. mallei LPS, MDDC
secreted high levels of TNF-a, IL-6, RANTES and IP-10 in
a CD14-dependent manner (Fig. 8). Taken together, these
results indicated that B. mallei LPS was a potent activator
of human APCs and was capable of stimulating cytokine
and chemokine responses that were consistent with the
activation of both hTLR4-MyD88-dependent (TNF-a and
IL-6) and -independent (RANTES and IP-10) signalling
pathways (Kawai et al., 2001; Re and Strominger, 2001;
Fitzgerald et al., 2003; Zughaier et al., 2005).
Discussion
Lipopolysaccharide antigens expressed by Burkholderia
pseudomallei and B. mallei are typically isolated from
whole cell pellets using a modiﬁed hot aqueous-phenol
extraction procedure (Brett and Woods, 1996; Burtnick
et al., 2002; Brett et al., 2003; Perry et al., 1995). Unfor-
tunately, the smooth LPS species expressed by these
Fig. 5. B. mallei LPS is a potent hTLR4 agonist. HEK
293-hTLR4/MD2-CD14 cells were stimulated with varying
concentrations of B. mallei GM3773 (open squares) or E. coli
O55:B5 (open circles) LPS following which the culture supernatants
were assayed for IL-8 production. HEK 293-hTLR2/CD14 were
similarly stimulated with B. mallei (ﬁlled squares) or E. coli (ﬁlled
circles) LPS and the culture supernatants assayed for IL-8
production. Values represent the means  SD of one experiment
assayed in triplicate. The ﬁgure is representative of three
independent experiments.
Fig. 6. Production of TNF-a, IL-6 and
RANTES by LPS stimulated THP-1 cells.
THP-1 cells were stimulated for 24 h with
10 ng ml
-1 of B. mallei GM3773 or E. coli
O55:B5 LPS following which the culture
supernatants were assayed for the production
of (A) TNF-a (B) IL-6 or (C) RANTES.
Unstimulated cells were included as a control.
Values represent the means  SD of four
independent experiments assayed in
duplicate.
Fig. 7. Production of TNF-a, IL-6 and
RANTES by LPS stimulated MDM. MDM cells
were stimulated for 24 h with 10 ng ml
-1 of
B. mallei GM3773 or E. coli O55:B5 LPS
following which the culture supernatants were
assayed for the production of (A) TNF-a (B)
IL-6 or (C) RANTES. Unstimulated cells were
included as a control. Values represent the
means of two readings. The ﬁgures are
representative of three independent
experiments.
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aqueous phase following extraction so that isolating
homogeneous preparations of these molecules can be a
challenge (Perry et al., 1995). For example, the high
molecular weight CPS expressed by virulent isolates of
B. mallei and B. pseudomallei partitions with the LPS into
the phenol phase so that size exclusion chromatography
is required to separate these carbohydrate antigens. In
order to simplify the task of obtaining highly puriﬁed
preparations of LPS for use in this study, we constructed
B. mallei GM3773. By using this CPS mutant, we were
able to isolate LPS antigens that were structurally identi-
cal to those expressed by the wild-type strain yet were
free from any contaminating CPS. In addition, because
B. mallei CPS mutants are attenuated for virulence
(DeShazer et al., 2001), working with strain
GM3773 minimized exposure to the virulent type strain.
Recent studies by Silipo et al. have demonstrated that
the human pathogen, Burkholderia cepacia BTS7,
expresses a complex mixture of tetra- and penta-acylated
lipid A species that are non-stoichiometrically substituted
with Ara4N residues (Silipo et al., 2005). Structural analy-
sis of the lipid A moieties isolated from this organism
indicated that the penta-acylated species with the highest
mass consisted of disaccharide backbones that were sub-
stituted with two phosphoryl-arabinosamine residues
[Arap4N-L-b-1-P-4-b-D-GlcpN-(1′-6)-a-D-GlcpN-1-P-1-b-
L-Arap4N] and possessed two ester linked C14:0(3-OH)
chains, two amide linked C16:0(3-OH) chains and an
acyloxyacyl linked C14:0 residue at the C-3 position of the
2′-C16:0(3-OH) chain. In addition, studies conﬁrmed that
the tetra-acylated species with the highest mass were
identical to the penta-acylated species except for the lack
of the 3′-ester linked C14:0(3-OH) chain. By utilizing a
combination of chemical analyses and MALDI-TOF-MS in
the present study, we have been able to demonstrate that
B. mallei also expresses a heterogeneous mixture of
tetra- and penta-acylated lipid A species that appear to be
non-stoichiometrically substituted with Ara4N residues. In
addition, all of the major molecular ion peaks identiﬁed in
this study were also observed during the analysis of the B.
cepacia BTS7 lipid A moieties. Interestingly, however,
none of the minor B. mallei lipid A species predicted to
bear acyloxyacyl linked C16:0 residues at the 2′-position
that were identiﬁed during our studies were shown to be
expressed by B. cepacia BTS7. At present, the signiﬁ-
cance of this phenomenon remains unknown.
Previous studies indicate that lipidAantigens consisting
of 1,4′-bisphosphorylated b(1′-6)-linked D-glucosamine
backbones substituted with two (R)-3-acyloxyacyl and two
(R)-3-hydroxyacyl residues in either the 4 + 2( E. coli-like)
or 3 + 3( Neisseria meningitidis-like) conﬁguration repre-
sent the optimal structures for activating human and
mammalian TLR4-complexes (Alexander and Rietschel,
2001; Erridge et al., 2002; Dixon and Darveau, 2005;
Zughaier et al., 2005; 2006). In addition, it has been
shown that lipid A antigens deviating from these patterns
tend to exhibit reduced biological activities in comparison
to these molecules (Kumazawa et al., 1988; Nakatsuka
et al., 1989; Takada and Kotani, 1989; Backhed et al.,
2003). Consistent with these ﬁndings, Bäckhed et al. have
demonstrated that LPS antigens isolated from wild-type
strains of E. coli stimulate signiﬁcantly higher levels of
IL-8 from human bladder carcinoma cells (T24 cells) than
penta-acylated LPS antigens isolated from waaN (lpxM)
mutants (Backhed et al., 2001). Interestingly, Ernst et al.
have also shown that LPS preparations obtained from
Pseudomonas aeruginosa clinical isolates expressing
Fig. 8. Production of TNF-a, IL-6, RANTES and IP-10 by LPS stimulated MDDC is CD14-Dependent. Prior to stimulation, the MDDC were
incubated for 30 min with an anti-CD14 antibody (black bars) or a non-speciﬁc isotype control (grey bars). The cells were then stimulated for
24 h with 10 ng ml
-1 of B. mallei GM3773 or E. coli O55:B5 LPS following which the culture supernatants were assayed for the production of
(A) TNF-a, (B) IL-6, (C) RANTES or (D) IP-10. Unstimulated cells were included as a control. Values represent the means of two readings.
The ﬁgures are representative of three independent experiments.
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robust pro-inﬂammatory responses from human macroph-
ages and endothelial cells than LPS preparations puriﬁed
from clinical isolates expressing only penta-acylated
species (Ernst et al., 1999; 2003; Hajjar et al., 2002). In
contrast to established structure/function paradigms,
however, our studies indicate that although devoid of
hexa-acylated species, B. mallei LPS is a potent hTLR4
agonist and is capable of stimulating human APCs in a
manner similar to E. coli LPS. Based upon these results,
it appears that by optimizing the length, number and order
of their lipidAfatty acids, organisms such as B. mallei and
B. cepacia are able to synthesize a mixture of tetra and
penta-acylated LPS antigens whose individual or com-
bined biological properties mimic those typically associ-
ated with hexa-acylated LPS preparations (Zughaier
et al., 1999; De Soyza et al., 2004; Bamford et al., 2006).
Capping of lipid A phosphates represents an important
molecular mechanism utilized by Gram-negative patho-
gens to resist the bactericidal effects of cationic antimi-
crobial peptides (CAPs) produced by host innate immune
responses (Vaara, 1992; Gunn et al., 1998; 2000; Gunn,
2001; Trent, 2004). By modifying lipid A phosphates with
amine-containing substituents like Ara4N and phosphoet-
hanolamine, pathogens such as Salmonella typhimurium
and Yersinia pestis can lower their affinity for CAPs and
cationic antibiotics by decreasing the overall negative
charge of their cell surfaces (Zhou et al., 2001; Kawahara
et al., 2002; Trent, 2004). In S. typhimurium, modiﬁcation
of lipid A moieties with Ara4N residues is governed by the
PmrA/PmrB two-component system which regulates the
expression of genetic loci necessary for the biosynthesis
of Ara4N (Soncini and Groisman, 1996). Transcription of
PmrA-regulated loci is induced by ferric iron (Fe+3), which
is sensed by the cognate sensor-PmrB, and by low con-
centrations of magnesium (Mg+2), which requires not only
PmrA and PmrB but also PhoP, PhoQ and PmrD (Grois-
man, 2001; Winﬁeld et al., 2005). Consistent with current
observations that B. mallei lipid A moieties are modiﬁed
with Ara4N residues, bioinformatics analyses have
revealed that a number of genetic loci (ugd, arnA, arnB,
arnC and arnT) known to be involved in the biosynthesis
of Ara4N and its transfer to S. typhimurium and E. coli
lipid A phosphates are also present in the genome of
B. mallei ATCC 23344 (Trent et al., 2001; Nierman et al.,
2004). Curiously, however, although a putative pmrA
homologue was identiﬁed during these analyses, no
obvious pmrB, pmrD, phoP or phoQ homologues were
found. Studies are ongoing in order to characterize the
mechanism(s) by which B. mallei modiﬁes lipid A moieties
with Ara4N residues and the potential signiﬁcance of
these modiﬁcations with regards to CAP resistance.
In addition to remodelling the charge characteristics of
their LPS antigens, S. typhimurium, P. aeruginosa and
Y. pestis are also capable of modifying the acylation pat-
terns of their lipidAmoieties in response to environmental
changes such as temperature, pH and cation concentra-
tions(Ernstet al.,1999;2006;Zhouet al.,2001;Kawahara
et al., 2002; Rebeil et al., 2004; 2006; Tran et al., 2005). In
particular, modiﬁcations resulting in the synthesis of tetra-
acylated species have been shown to signiﬁcantly affect
virulence phenotypes as well as play an important role
in modulating mammalian TLR4-dependent immune
responses (Ernst et al., 1999; Hajjar et al., 2002; Backhed
et al., 2003; Rebeil et al., 2004). Recently, Rebeil et al.
demonstrated that when grown at 21°C, Y. pestis
expressed a heterogeneous mixture of LPS antigens in
whichhexa-acylatedspeciespredominated,whileat37°C,
the organism expressed a mixture of LPS species in which
tetra-acylated forms of the antigen predominated (Rebeil
et al., 2004). During the study, it was also shown that LPS
preparations isolated from Y. pestis grown at 37°C stimu-
lated signiﬁcantly less TNF-a production from human
peripheral blood monocytes than did LPS preparations
puriﬁed from the organism when grown at 21°C. Based
upon these ﬁndings it was suggested that the ability of
Y. pestis to modify LPS acylation patterns in response to
changing temperature may enhance its ability to survive
during transitions from its ﬂea vector to mammalian hosts.
Morerecently,Reifeet al.demonstratedthattetra-acylated
LPS species expressed by Porphyromonas gingivalis are
potent TLR4 antagonists and that by altering the relative
amounts these antigens in its outer membrane the organ-
ismmaybecapableofmodulatinghostimmuneresponses
(Reife et al., 2006). Interestingly, studies have shown that
LPS preparations from a clinical isolate of Burkholderia
cenocepacia expressing only penta-acylated species
stimulated strongerTNF-a and IL-6 responses from U-937
cells than from LPS preparations puriﬁed from a clinical
isolate of Burkholderia multivorans expressing both tetra-
and penta-acylated species (De Soyza et al., 2004).
In the present study we have demonstrated that
B. mallei expresses a mixture of tetra- and penta-acylated
LPS species that in combination exhibit some unique
biological properties. In order to fully characterize the
signiﬁcance of this heterogeneity, however, further studies
will be required to elucidate the speciﬁc activities of these
individual LPS species. Whether or not changes in envi-
ronmental conditions/stimuli modulate LPS acylation
patterns and biological activity also remains to be experi-
mentally deﬁned. Studies are ongoing to address these
important issues.
Experimental procedures
Bacterial strains and growth conditions
The bacterial strains used in this study are described in
Table 2. Escherichia coli strains were grown at 37°C on LB
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weregrownat37°CinLBLbrothoronLBLagarsupplemented
with 4% glycerol. When appropriate, antibiotics were used at
the following concentrations: 10 mgm l
-1 gentamicin or
15 mgm l
-1 polymyxin B for E. coli and 5 mgm l
-1 gentamicin for
B. mallei. Bacterial stocks were maintained at -80°C as 20%
glycerolsuspensions.AllstudiesutilizingviableB. malleiwere
conductedunderbiosafetylevelthreecontainmentconditions.
Recombinant DNA techniques
DNAmanipulations were performed using standard methods.
Polymerase chain reaction (PCR) and restriction enzyme
digested products were puriﬁed using a QIAquick Gel Extrac-
tion Kit (Qiagen). The plasmids described in Table 2 were
puriﬁed using a QIAprep Spin Miniprep Kit (Qiagen). Chro-
mosomal DNA was isolated using a Wizard™ Genomic DNA
Isolation Kit (Promega). Chemically competent E. coli were
transformed using standard methods.
Mutant construction
The B. mallei GM3773 CPS mutant was constructed essen-
tially as previously described (DeShazer et al., 2001; Burtnick
et al., 2002). Brieﬂy, a 547 bp fragment internal to the wcbB
allele was PCR ampliﬁed from puriﬁed B. mallei ATCC 23344
chromosomal DNA using the wcbB-iF and wcbB-iR primer
pair (Table 2); the BsaI/EcoRI and BsaI/NheI restriction sites
in the linker regions are underlined. The ampliﬁed product
was then cloned into pGSV3. The resulting suicide plasmid,
pGMwcbB, was mobilized into ATCC 23344 via conjugative
mating using E. coli S17-1. Site speciﬁc recombination of the
plasmid into the ATCC 23344 chromosome was veriﬁed via
PCR using the wcbB-up and MB1ori-P1 primer pair (Table 2).
Lipopolysaccharide puriﬁcation and lipid a isolation
LBL broth inoculated with B. mallei ATCC 23344 or GM3773
was incubated overnight at 37°C with vigorous shaking. Cell
pellets were subsequently obtained by centrifugation and
extracted using a modiﬁed hot aqueous-phenol procedure
(Perry et al., 1995). Following extraction, the resulting phenol
and aqueous phases were combined and dialysed in distilled
water to remove the phenol. The dialysates were then clari-
ﬁed by centrifugation and concentrated by lyophilization.
The crude preparations were solubilized (20 mg ml
-1)i nR D
buffer [10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM CaCl2,
50 mgm l
-1 RNase A and 50 mgm l
-1 DNase I] and incubated
for 3 h with shaking at 37°C. Proteinase K was then added to
a ﬁnal concentration of 50 mgm l
-1 and the digests were incu-
bated for an additional 3 h at 60°C. The enzymatic digests
were clariﬁed by centrifugation and the supernatants ﬁlter
sterilized. LPS was then isolated from the supernatants as
precipitated gels following three rounds of ultracentrifugation
at 100 000 g and 4°C. After the ﬁnal spin, the gel-like pellets
were resuspended in pyrogen-free water and lyophilized. To
remove contaminating phospholipids, the lyophilized LPS
samples were repeatedly extracted with 90% EtOH. Lipid A
was isolated from the puriﬁed LPS samples via mild acid
hydrolysis. Brieﬂy, LPS was hydrolysed for 4 h at 95°C in
0.1 M NaOAc (pH 4.5). The lipidAfraction was then removed
by extraction with chloroform : methanol (2:1) and dried
under a gentle stream of air and lyophilized.
SDS-PAGE, immunoblotting and ELISA analyses
Puriﬁed samples were solubilized in 1¥ SDS-PAGE sample
buffer and heated to 100°C for 5 min prior to electrophoresis
on 12% Express Gels (ISC BioExpress). The LPS was visu-
alized by silver staining as previously described (Fomsgaard
et al., 1990). Immunoblot analysis was performed as previ-
ously described (Burtnick et al., 2002). ELISA were per-
formed essentially as previously described (DeShazer et al.,
1998). The primary antibodies used in this study were the
O-antigen speciﬁc 3D11 monoclonal antibody (mAb;
Research Diagnostics) and the CPS speciﬁc MCA147 mAb
(Reckseidler-Zenteno et al., 2005). The secondary antibodies
used were anti-mouse IgG or IgM horse radish peroxidase
conjugates (Sigma).
Glycosyl composition analysis
Per-O-trimethylsilyl (TMS) derivatives of monosaccharide
methyl glycosides produced from the acidic methanolysis of
Table 2. Bacterial strains, plasmids and primers used in this study.
Strain, plasmid or primer Description Source or reference
Strain
E. coli
TOP10 High efficiency transformation: Gm
s Invitrogen
S17-1 Mobilizing strain; transfer genes of RP4 integrated in
chromosome: Gm
s,P m
s
Simon et al. (1983)
B. mallei
ATCC 23344 Type strain; isolated in 1944 from a human case of glanders: Gm
s,P m
r Yabuuchi et al. (1992)
GM3773 ATCC 23344::pGMwcbB: Gm
r,P m
r This study
Plasmids
pGSV3 Mobilizable suicide vector: Gm
r DeShazer et al. (2001)
pGMwcbB pGSV3 containing a 547 bp PCR fragment internal to wcbB:G m
r This study
Primers
wcbB-iF 5′-CCCAACGGTCTCAAATTCGATATTCAGGCTAGCCGCGC-3′ This study
wcbB-iR 5′-CCCAACGGTCTCGCTAGTGACGTTCTCGCATTCCCAGCCTCG-3′ This study
wcbB-up 5′-ACGAAGTCCGCCGTGTTTCGATCAGC-3′ This study
MB1ori-P1 5′-GAAGATCCTTTGATCTTTTCTACGG-3′ This study
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mass spectrometry (GC/MS). The methyl glycosides were
prepared by heating the dried lipid A samples in acidiﬁed
methanol (1 M HCl) at 80°C for 18–22 h. Following this, the
samples were re-N-acetylated with pyridine and acetic anhy-
dride in order to facilitate the detection of amino sugars. The
samples were then per-O-trimethylsilylated via treatment with
Tri-Sil (Pierce) at 80°C for 30 min. GC/MS analysis of the
TMS methyl glycosides was performed on a HP 5890 GC
interfaced with a 5970 MSD using aAll Tech EC-1 fused silica
capillary column (30 m ¥ 0.25 mm ID).
Fatty acid analysis
Methyl ester derivatives of the fatty acids generated by acidic
methanolysis of the lipidAsamples, were dried, resuspended
in hexane and analysed by GC/MS to determine total fatty
acid content. In order to detect O-linked fatty acids, the lipid
A samples were suspended in alkaline methanol (0.25 M
NaOMe), incubated overnight at 37°C and then neutralized
with an equal volume of 0.25 M HCl. The fatty acid methyl
esters were then extracted with 0.15 volumes of chloroform
and analysed by GC/MS after a partial drying under a gentle
stream of dry air. In addition to using the All Tech EC-1 fused
silica capillary column, GC was also performed using a
Supelco SP 2380 capillary column equipped with a FID
detector and a bimodal temperature gradient starting at
130°C and increasing at 4°C per minute to 190°C followed by
a 1 min hold at 190°C and a 17°C per minute gradient to
260°C and 3 min hold.
Mass spectrometry
Matrix-assisted laser desorption/ionization time-of-ﬂight
mass spectrometry (MALDI-TOF-MS) was performed in the
negative-ion mode on a Voyager DE-STR mass spectrometer
(Applied Biosystems). Lipid A samples in chloroform : metha-
nol (2:1) were mixed on target with 2,5-dihydroxybenzoic acid
(500 mM in anhydrous methanol) via the dried droplet
method. The following parameters were used: N2 laser,
337 nm, accelerating voltage 20 kV with delayed extraction
and mass range of 500–5000. MALDI-TOF spectrometry was
also performed on an Applied Biosystems 4700 Proteomics
Analyzer in the positive ion reﬂector mode.
Cell culture
Human embryonic kidney 293 (HEK 293) cells transfected
with human MD2-CD14 (HEK 293-hMD2-CD14; Invivogen),
human TLR2/CD14 (HEK 293-hTLR2/CD14; Invivogen) or
human TLR4/MD2-CD14 (HEK 293-hTLR4/MD2-CD14; Invi-
vogen) were maintained at 37°C with 5% CO2 in Dulbecco’s
modiﬁed Eagle’s medium (Invitrogen) supplemented with
10% heat-inactivated (HI) fetal bovine serum (FBS),
10 mgm l
-1 Blasticidin S and 50 mgm l
-1 Hygromycin B
(Invivogen). Prior to stimulation with LPS, the HEK 293 cell
lines were transferred into 24-well tissue culture plates at
5 ¥ 10
5 cells well
-1. U-937 and THP-1 human monocytes
(ATCC) were maintained at 37°C with 5% CO2 in RPMI 1640
medium (Invitrogen) supplemented with 10% HI FBS and
100 mgm l
-1 Normocin™ (Invivogen). To differentiate the
monocytes into macrophage-like cells, the U-937 and THP-1
cells were transferred into 24-well tissue culture plates at
1 ¥ 10
5 cells well
-1 and incubated at 37°C with 5% CO2 for
36 h in the presence of 50 ng ml
-1 phorbol myristate acetate.
Prior to stimulation with LPS, the differentiated cells were
washed with Hanks balanced salt solution (Invitrogen).
Human monocyte-derived macrophage and
dendritic cells
Human peripheral blood mononuclear cells were isolated
from buffy coats by centrifugation through a Ficoll-Paque
Plus density gradient (Amersham Pharmacia Biotech). Cells
were enriched for monocytes (CD14+ cells) using a Rosset-
teSep Monocyte Enrichment Kit (Stem Cell Technologies).
Macrophages (MDM) were obtained by resuspending the
monocytes (1 ¥ 10
6 cells ml
-1)i nM F medium (RPMI 1640,
10% HI FBS, 50 ng ml
-1 recombinant human M-CSF; Pepro-
tech) and then culturing them at 37°C with 5% CO2 for 7 days
with the addition of fresh cytokine on day three. On day
seven, the adherent cells were washed once with phosphate-
buffered saline (PBS) and then incubated on ice for 20 min
in PBS. The cells were then harvested by gentle scraping
and centrifugation (500 g), resuspended in MF medium
and transferred into 24-well tissue culture plates at
1 ¥ 10
5 cells well
-1 prior to LPS stimulation. Monocyte-
derived dendritic cells (MDDC) were isolated and the CD14
blocking studies were performed as previously described
(Shannon et al., 2005).
Lipopolysaccharide stimulation assays and
cytokine quantiﬁcation
Prior to use, the E. coli O55:B5 (Sigma) and B. mallei
GM3773 LPS samples were repeatedly extracted with 90%
EtOH to remove any contaminating phospholipids (Zughaier
et al., 2005). LPS stocks were prepared in pyrogen free
water (Cambrex) and were quantiﬁed on a w/v basis. HEK
293 cell lines were stimulated for 6 h with varying concen-
trations (0.1–100 ng ml
-1) of GM3773 or O55:B5 LPS fol-
lowing which the culture supernatants were harvested and
assayed for IL-8 production using Human IL-8 Chemilumi-
nescent ELISA Kits (Endogen). THP-1, U-937, MDM and
MDDC cells were stimulated for 24 h with 10 ng ml
-1 of
GM3773 or O55:B5 LPS following which the culture super-
natants were harvested and assayed for TNF-a, IL-6,
RANTES and IP-10 production using human SearchLight
Custom Multiplex Arrays (Pierce).
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